Cargando…
Death receptors as targets for anti-cancer therapy
Human tumour cells are characterized by their ability to avoid the normal regulatory mechanisms of cell growth, division and death. The classical chemotherapy aims to kill tumour cells by causing DNA damage-induced apoptosis. However, as many tumour cells posses mutations in intracellular apoptosis-...
Autores principales: | Papenfuss, Kerstin, Cordier, Stefanie M, Walczak, Henning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828874/ https://www.ncbi.nlm.nih.gov/pubmed/19210756 http://dx.doi.org/10.1111/j.1582-4934.2008.00514.x |
Ejemplares similares
-
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
por: Montinaro, Antonella, et al.
Publicado: (2022) -
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
por: Kundu, Manjari, et al.
Publicado: (2022) -
Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?
por: Haschka, Manuel, et al.
Publicado: (2018) -
Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
por: Fu, Wencheng, et al.
Publicado: (2023) -
Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy
por: Wolska, Nina, et al.
Publicado: (2019)